JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation [Yahoo! Finance]
Form 8-K Jasper Therapeutics, For: Jan 08
Form 8-K Jasper Therapeutics, For: Jan 02
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: MARTELL RON
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: Mahal Jeetinder Singh
Form 4 Jasper Therapeutics, For: Jan 02 Filed by: CROSS HERB
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.